USA - NASDAQ:TMDX - US89377M1099 - Common Stock
The current stock price of TMDX is 131.54 USD. In the past month the price increased by 13.7%. In the past year, price increased by 59.64%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.77 | 215.16B | ||
| ISRG | INTUITIVE SURGICAL INC | 62.05 | 191.53B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.14 | 149.24B | ||
| SYK | STRYKER CORP | 27.05 | 136.19B | ||
| MDT | MEDTRONIC PLC | 16.4 | 116.34B | ||
| BDX | BECTON DICKINSON AND CO | 12.52 | 51.22B | ||
| IDXX | IDEXX LABORATORIES INC | 52.42 | 50.36B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.08 | 48.41B | ||
| RMD | RESMED INC | 24.94 | 36.03B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.33 | 34.22B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.46 | 26.31B | ||
| STE | STERIS PLC | 24.71 | 23.21B |
TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 728 full-time employees. The company went IPO on 2019-05-02. The firm specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. The company also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
TRANSMEDICS GROUP INC
200 Minuteman Road
Andover MASSACHUSETTS 01810 US
CEO: Waleed H. Hassanein
Employees: 728
Phone: 19785520900
TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 728 full-time employees. The company went IPO on 2019-05-02. The firm specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. The company also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
The current stock price of TMDX is 131.54 USD. The price decreased by -3.13% in the last trading session.
TMDX does not pay a dividend.
TMDX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
TMDX stock is listed on the Nasdaq exchange.
The PE ratio for TRANSMEDICS GROUP INC (TMDX) is 53.26. This is based on the reported non-GAAP earnings per share of 2.47 and the current share price of 131.54 USD.
TRANSMEDICS GROUP INC (TMDX) has a market capitalization of 4.48B USD. This makes TMDX a Mid Cap stock.
ChartMill assigns a technical rating of 9 / 10 to TMDX. When comparing the yearly performance of all stocks, TMDX is one of the better performing stocks in the market, outperforming 87.18% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to TMDX. TMDX has an average financial health and profitability rating.
Over the last trailing twelve months TMDX reported a non-GAAP Earnings per Share(EPS) of 2.47. The EPS increased by 162.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 13.49% | ||
| ROA | 8.05% | ||
| ROE | 22.53% | ||
| Debt/Equity | 1.61 |
18 analysts have analysed TMDX and the average price target is 149.33 USD. This implies a price increase of 13.52% is expected in the next year compared to the current price of 131.54.
For the next year, analysts expect an EPS growth of 138.61% and a revenue growth 39.65% for TMDX